Digital International Liver Congress™ 2020

Nidufexor lowers ALT, hepatic fat in patients with NASH

Elaine Soliven, 20200930000000

Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.

Liver cirrhosis: Repeat FIB-4 test predicts who’s at risk

Elvira Manzano, 20200929090000

A repeat fibrosis-4 (FIB-4) test ably identifies individuals at greatest risk for liver cirrhosis in a new study.

Daily albumin infusion fails to reduce infection, renal dysfunction in decompensated cirrhosis

Roshini Claire Anthony, 20200921200001

Daily albumin infusion to achieve serum albumin levels of ≥30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.

Aldafermin significantly reduces liver fat in patients with NASH

Elaine Soliven, 20200911000000

Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.

Switch from TDF to TAF does not affect viral suppression in chronic HBV

Roshini Claire Anthony, 20200910200001

In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.

ATLAS: Some hits, some misses for combo therapy in NASH

Pearl Toh, 20200910143500

The combination therapy of cilofexor (CILO) and firsocostat (FIR) missed the primary endpoint but achieved improvements in other secondary parameters including fibrosis markers, disease activity, and liver function in patients with fibrosis due to NASH*, according to the ATLAS trial presented at digital ILC 2020.

Diagnosing, monitoring NASH, fibrosis: Will noninvasive tools work?

Audrey Abella, 20200910100000

Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).

Trivalent hep B vaccine yields robust immune response

Pearl Toh, 20200907150010

A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.

NAFLD remains a top public health threat

Tristan Manalac, 20200907090000

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related deaths and is associated with a variety of malignancies, according to a new study presented at the Digital International Liver Congress (ILC) 2020.

Gut bacteria implicated in a spectrum of important neurological pathologies

Faecal microbiota transplantation leads to short-term improvements in severe alcoholic hepatitis

Tristan Manalac, 20200905090000

Faecal microbiota transplantation (FMT) may be a viable treatment option for patients with severe alcoholic hepatitis (SAH), reports a study presented at the Digital International Liver Congress (ILC) 2020.